Exhibit 5.2
June 24, 2020
Takeda Pharmaceutical Company Limited
1-1, Nihonbashi-Honcho2-Chome
Chuo-ku, Tokyo103-8668
Japan
Takeda Pharmaceutical Company Limited
Registration Statement on FormF-3
Dear Sirs:
We have acted as legal counsel to Takeda Pharmaceutical Company Limited (the “Company”) with respect to the laws of Japan in connection with the Registration Statement on FormF-3 which the Company filed with the United States Securities and Exchange Commission (the “Commission”) on June 24, 2020 (the “Registration Statement”) to register senior debt securities (the “Securities”) under the United States Securities Act of 1933, as amended (the “Securities Act”).
Upon the request by the Company, we are furnishing our opinion to be filed as Exhibit 5.2 to the Registration Statement. For such purpose, we have examined the following documents:
(i) | Certified copies of the Articles of Incorporation and the Regulations of the Board of Directors of the Company; |
(ii) | a form of the Underwriting Agreement (the “Underwriting Agreement”) to be executed between the Company and underwriters; |
(iii) | a form of the Indenture (the “Indenture”) to be executed between the Company and a trustee (the “Indenture”, together with the Underwriting Agreement, the “Transaction Agreements”); |
(iv) | an extracted copy of the minutes of the meetings of the Board of Directors of the Company held on June 24, 2020; |
(v) | a certified copy of the Certificate of Complete History of Company Register of the Company dated June 17, 2020; and |
(vi) | a conformed copy of the Registration Statement and all exhibits thereto. |
We have also examined such other certificates, corporate and other records of the Company and such other documents and records, and considered such questions of law, as we have deemed necessary or appropriate for the purpose of furnishing the opinion hereinafter set forth. We have relied, as to certain factual matters, upon the documents referred to in item (i) through (vi) above, and other certificates of officers or other authorized persons of the Company or public officials as we have deemed appropriate as a basis for the opinion expressed herein.
On the basis of such examination, and subject to the further assumptions and qualifications set forth below, we are of the opinion that insofar as the laws of Japan, in effect as of the date hereof, are concerned:
When (i) the terms of the Securities have been duly established in conformity with the Indenture and (ii) the Securities are duly executed, authenticated, issued and delivered in accordance with the provisions of the Indenture against receipt by the Company of the purchase moneys for the Securities in accordance with the Underwriting Agreement, and assuming that the Securities will create valid, legally binding obligations in respect of the Securities under the law of the State of New York by which they are stipulated to be governed, the Securities will constitute valid and legally binding obligations of the Company enforceable in accordance with their terms.